Latest Capital Raises News

Altitude Minerals is gearing up for significant drilling campaigns in New South Wales and Nevada, backed by a recent $1.15 million capital raise to fund exploration and project advancement.

Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.

Tivan Limited has locked in a minimum $15 million funding package through a $10 million option underwriting agreement and a $5 million share placement with strategic investor ETFS Capital, supporting accelerated development across its Australian and Timor-Leste projects.

Great Western Exploration has kicked off a 3,000m air core drilling program at its Diorama copper-gold target in Western Australia, aiming to test a large copper anomaly indicative of DeGrussa-style VHMS mineralisation.

Megaport has landed four major AI infrastructure contracts worth A$459 million, fueling its plan to build a globally-distributed AI inference cloud supported by a new A$350 million GPU Pool. The company is raising A$827 million through a fully underwritten entitlement offer to fund these initiatives and future growth.

Pacific Edge has secured NZ$36.1 million through a combination of a NZ$25.4 million placement and a significantly oversubscribed retail offer, reinforcing its strategic position to expand the Cxbladder cancer diagnostic platform.

Qoria Limited has dispatched its Scheme Booklet to shareholders detailing the proposed acquisition by Aura Consolidated Group. While the independent expert finds the deal not fair but reasonable, Qoria’s board unanimously recommends approval, pending no superior proposal.

Dome Gold Mines (ASX:DME) is raising up to AUD 2 million through unsecured convertible notes to fast-track its Sigatoka feasibility study, mining lease application, and copper-gold exploration amid rising metal prices.

Stavely Minerals has issued its Tranche 2 placement shares following shareholder approval, with key investors increasing stakes. The company eyes a mid-year scoping study and imminent diamond drilling at promising copper-gold-silver and gold prospects.

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.

The Takeovers Panel has declined to investigate Skin Elements Limited's allegations of undisclosed investor associations following a $2.5 million placement, after 62 Capital agreed to waive transfer restrictions on placement securities.

Bio-Gene Technology has expanded its capital raise to $2.775 million through a share placement priced at 2.5 cents, attaching options exercisable at 3.5 cents pending shareholder approval.